RECOMBINANT HUMAN INTERFERON ALPHA 2 IN HIGH RISK, RESECTED MELANOMA PATIENTS

重组人干扰素 ALPHA 2 用于高危黑色素瘤切除患者

• 批准号: 3740073
• 负责人: WILLIAM A. ROBINSON
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3740073
• 关键词: human subject; human therapy evaluation; interferon alpha; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; recombinant proteins

The aim of these studies is to determine whether a short course of alpha interferon in a dosage of 2 million units per meter squared subcutaneously for 12 weeks can reduce the risk of recurrence in patients with completely resected malignant melanoma. This is an open ended study, with all patients receiving alpha interferon. They are then followed for recurrence, sites of recurrence and survival.

这些研究的目的是确定短期阿尔法治疗是否 每平方米2百万单位的干扰素 皮下注射12周可以降低复发的风险， 恶性黑色素瘤完全切除的患者。这是一个开放 研究结束，所有患者均接受α干扰素治疗。然后将它们 随访复发、复发部位和生存率。